Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Minor site revision update to v3.4.2 from v3.4.1; no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-14T12:58:26.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.1 and no longer displays Revision: v3.4.0.
    Difference
    0.1%
    Check dated 2026-02-07T07:18:45.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    A glossary toggle was added; QC-related metadata labels were updated to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels.
    Difference
    0.3%
    Check dated 2026-01-24T04:56:47.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page revision was updated from v3.3.3 to v3.3.4. No study content or critical information appears to have changed; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-17T03:48:07.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    Footer now shows Revision: v3.3.3; references to HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.
    Difference
    0.1%
    Check dated 2025-12-19T09:58:51.000Z thumbnail image
  7. Check
    89 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.2, replacing Revision: v3.3.1.
    Difference
    0.1%
    Check dated 2025-11-27T23:17:57.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.